Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6484891 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL5525558 | 1.00 | SMN1; SMN2 (0.49) | SMN1; SMN2MAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL2205707 | 0.90 | MAPT (0.51) | SMN1; SMN2MAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL5078615 | 0.90 | MAPT (0.51) | SMN1; SMN2MAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL2205704 | 0.90 | MAPT (0.51) | SMN1; SMN2MAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL6489181 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTL3MBTL1ALDH1A1RAB9A | |
| SCHEMBL14615017 | 0.86 | MAPT (0.44) | SMN1; SMN2MAPTHPGDALDH1A1RAB9A | |
| SCHEMBL6475019 | 0.86 | MAPT (0.44) | SMN1; SMN2MAPTL3MBTL1HPGDALDH1A1 | |
| SCHEMBL5520040 | 0.86 | MAPT (0.44) | SMN1; SMN2MAPTHPGDALDH1A1RAB9A | |
| SCHEMBL6822506 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2MAPTL3MBTL1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043035-A1 | Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-02-22 | — | — | US | disclosed |
| EP-1678128-A1 | NOVEL COMPOUNDS AND THEIR USE IN MEDICINE: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Reddy's Laboratories Ltd. (IN) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040104-A1 | NOVEL COMPOUNDS AND THEIR USE IN MEDICINE: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-06 | — | — | WO | disclosed |
| US-6867218-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2005-03-15 | — | — | US | disclosed |
| US-6737438-B2 | EFFECTIVE IN MULTIDRUG RESISTANT MICE | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-05-18 | — | — | US | disclosed |
| US-20040053991-A1 | Substituted 1,2,4-trioxanes useful as antimalarial agents and a process for the preparation thereof | COUNCIL SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-03-18 | — | — | US | disclosed |
| US-20030195200-A1 | Compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-10-16 | — | — | US | disclosed |
| WO-2003082852-A1 | NOVEL SUBSTITUTED 1,2,4-TRIOXANES USEFUL AS ANTIMALARIAL AGENTS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2003-10-09 | — | — | WO | disclosed |
| US-6555577-B1 | For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| EP-1254101-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | Novo Nordisk A/S (DK) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
| US-4344966-A | Anti-inflammatory 1-alkyl-1-phenyl-butanes | SANDOZ, INC. (US) | 1982-08-17 | — | — | US | disclosed |
| US-4335124-A | ANTIINFLAMMATORY AGENTS | SANDOZ, INC. (US) | 1982-06-15 | — | — | US | disclosed |
| US-4273787-A | ANTIINFLAMMATORY AGENTS | SANDOZ, INC. (US) | 1981-06-16 | — | — | US | disclosed |
| US-4081476-A | ANTIINFLAMMATORY | SANDOZ, INC. (US) | 1978-03-28 | — | — | US | disclosed |
| US-3980795-A | Pyrazolidinones and a process for their preparation | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1976-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053991-A1 | Substituted 1,2,4-trioxanes useful as antimalarial agents and a process for the preparation thereof | DHPS, TBXAS1, ABCC1 | SMN1; SMN2 4624/4885MAPT 3696/4885L3MBTL1 3204/4885 |
| US-20070043035-A1 | Novel compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, LIPC | SMN1; SMN2 4582/4885MAPT 4179/4885L3MBTL1 4808/4885 |
| US-20030195200-A1 | Compounds, their preparation and use | PPARG, PPARA, PPARD | SMN1; SMN2 3127/4885MAPT 3845/4885L3MBTL1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.